Nelson’s syndrome: physiopathology, management and prognosis

References

• Nelson DH, Meakin JW, Dealy JB Jr et al. ACTH-producing tumor of the pituitary gland. N. Engl. J. Med.259(4), 161–164 (1958).
   PubMed Web of Science ®Google Scholar
• Nelson DH, Meakin JW, Thorn GW. ACTH-producing pituitary tumor following adrenalectomy for Cushing’s syndrome. Ann. Int. Med.52, 560–569 (1960).
   PubMed Web of Science ®Google Scholar
• Nelson DH, Hume DM. Corticosteroid secretion in the adrenal venous blood of the hypophysectomized dog as an assay for ACTH. Endocrinology57, 184–192 (1955).
   PubMedGoogle Scholar
• Liddle GW, Island D, Meador CK. Normal and abnormal regulation of corticotrophin secretion in man. Recent Prog. Horm. Res.18, 125–166 (1962).
   Google Scholar
• Summers SA, Nelson DH. A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing’s syndrome. Diabetes54, 591–602 (2005).
   PubMedGoogle Scholar
• Hornyak M, Weiss MH, Nelson DH, Couldwell WT. Nelson syndrome: historical perspectives and current concepts. Neurosurg. Focus23(3), E12, 1–7 (2007).
   PubMedGoogle Scholar
• Nowakowski H, Breustedt H-J, Mischke W, Montz HR. Anterior pituitary function in hypothalamic Cushing’s syndrome with and without ACTH producing adenomas. In: Treatment of Pituitary Adenomas. Fahlbusch R, van Werder K (Eds). Georg Thieme, Stuttgart, Germany 330–332 (1978).
   Google Scholar
• Lüdecke DK, Kautzky R, Bansemer J, Resetic J, Montz HR. ACTH secretion and neurosurgical management of Cushing’s disease. In: Treatment of Pituitary Adenomas. Fahlbusch R, van Werder K (Eds). Georg Thieme, Stuttgart, Germany 333–339 (1978).
   Google Scholar
• Banasiak MJ, Malek AR. Nelson’s syndrome: comprehensive review of pathophysiology, diagnosis, and management. Neurosurg. Focus23, 1–10 (2007).
   PubMedGoogle Scholar
• Ross EJ, Linch DC. Cushing’s syndrome – killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancetii, 646–649 (1982).
   Google Scholar
• Newell-Price J, Bertagna X, Grossman A, Nieman LK. Cushing’s syndrome. Lancet367(9522), 1605–1617 (2006).
   PubMed Web of Science ®Google Scholar
• Assié G, Bahurel H, Coste J et al. Corticotroph tumor progression after adrenalectomy in Cushing’s disease: a reappraisal of Nelson’s syndrome. J. Clin. Endocr. Metab.92(1), 172–179 (2007).
   PubMed Web of Science ®Google Scholar
• Hopwood NJ, Kenny FM. Incidence of Nelson’s syndrome after adrenalectomy for Cushing’s disease in children: results of a nationwide survey. Am. J. Dis. Child131, 1353–1356 (1977).
   PubMedGoogle Scholar
• Thomas CG Jr, Smith AT, Benson M, Griffith J. Nelson’s syndrome after Cushing’s disease in childhood: a continuing problem. Surgery96, 1067–1077 (1984).
   PubMed Web of Science ®Google Scholar
• Kasperlik-Zaluska AA, Bonicki W, Jeske W, Janik J, Zgliczynski W, Czernicki Z. Nelson’s syndrome – 46 years later: clinical experience with 37 patients. Zentralblatt Neurochir.67, 14–20 (2006).
   PubMedGoogle Scholar
• Kasperlik-Zaluska AA, Nielubowicz J, Wislawski J et al. Nelson’s syndrome: incidence and prognosis. Clin. Endocrinol.19, 693–698 (1983).
   PubMed Web of Science ®Google Scholar
• Wislawski J, Kasperlik-Zaluska AA, Migdalska B et al. Results of neurosurgical treatment by a transsphenoidal approach in 10 patients with Nelson’s syndrome. J. Neurosurg.62, 68–71 (1985).
   PubMedGoogle Scholar
• Hardy J. Transsphenoidal hypophysectomy, J. Neurosurg.34, 582–594 (1971).
   PubMed Web of Science ®Google Scholar
• Aniszewski J, Sawka A, Young WJ. The Nelson–Salassa syndrome: a long term follow-up study. Presented at: The 81st Annual Meeting of the Endocrine Society. San Diego, CA, USA 12–15 June 1999 (Abstract OR 42–44).
   Google Scholar
• Kasperlik-Zaluska AA, Walecki J, Brzezinski J et al. MRI versus CT in the diagnosis of Nelson’s syndrome. Eur. Radiol.7, 106–109 (1997).
   PubMedGoogle Scholar
• Jenkins PJ, Trainer PJ, Plowman PN. The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing’s syndrome. J. Clin. Endcrinol. Metab.79, 165–171 (1994).
   PubMedGoogle Scholar
• Kelly PA, Samandouras G, Grossman AB, Afshar F, Besser GM, Jenkins PJ. Neurosurgical treatment of Nelson’s syndrome. J. Clin. Endcrinol. Metab.87, 5465–5469 (2002).
   PubMed Web of Science ®Google Scholar
• Gil-Cardenas A, Herrera M, Diaz-Polanco A, Rios JM, Pantoja JP. Nelson’s syndrome after bilateral adrenalectomy for Cushing’s disease. Surgery141, 147–152 (2007).
   PubMed Web of Science ®Google Scholar
• Kasperlik-Zaluska A, Hartwig W, Wislawski J, Guiot G. Nelson’s syndrome following bilateral total adrenalectomy. Endokrynol. Pol.27, 401–408 (1976).
   PubMedGoogle Scholar
• Kasperlik-Zaluska AA, Walecki J, Jeske W et al. Early diagnosis of Nelson’s syndrome. J. Mol. Neurosci.7, 87–90 (1996).
   PubMedGoogle Scholar
• Kemink I, Pieters G, Hermus A, Smals A, Kloppenborg P. Patient’s age is a simple predictive factor for the development after total adrenalectomy for Cushing’s disease. J. Clin. Endcrinol. Metab.79, 887–889 (1994).
   PubMed Web of Science ®Google Scholar
• Karl M, Von Wichert G, Kempter E et al. Nelson’s syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene. J. Clin. Endcrinol. Metab.81, 124–129 (1996).
   PubMed Web of Science ®Google Scholar
• Bonicki W, Kasperlik-Zaluska A, Koszewski W, Zgliczynski W, Wislawski J. Pituitary apoplexy: endocrine, surgical and oncological emergency. Incidence, clinical course and treatment in reference to 799 cases of pituitary adenomas. Acta Neurochir.120, 118–122 (1993).
   PubMedGoogle Scholar
• Lisser H. Hypophysectomy in Cushing’s disease. J. Nerv. Ment. Dis.99, 727–733 (1944).
   Google Scholar
• Tabaee A, Anand VK, Barron Y et al. Endoscopic pituitary surgery: a systematic review and metaanalysis. J. Neurosurg.111, 545–554 (2009).
   PubMed Web of Science ®Google Scholar
• Dehdashti AR, Ganna A, Karabatsou K, Gentili F. Pure endoscopic endonasal approach for pituitary adenomas. Neurosurgery62(5), 1006–1015 (2008).
   PubMed Web of Science ®Google Scholar
• O’Malley BW Jr, Grady MS, Gabel BC et al. Comparison of endoscopic and microscopic removal of pituitary adenomas: single-surgeon experience and the learning curve. Neurosurg. Focus25(6), E10 (2008).
   PubMed Web of Science ®Google Scholar
• Mauermann WJ, Sheehan JP, Chernavsky DR, Laws ER, Steiner L, Vance ML. Gamma knife surgery for adrenocorticotropic hormone-producing pituitary adenomas after bilateral adrenalectomy. J. Neurosurg.106, 988–993 (2007).
   PubMedGoogle Scholar
• Vik-Mo EO, Oksnes M, Pedersen PH et al. Gamma knife stereotactic radiosurgery of Nelson syndrome. Eur. J. Endocrinol.160(2), 143–148 (2008).
   PubMedGoogle Scholar
• Laws ER. Radiosurgery for pituitary tumors: has it come of age? Meet the Professor Session. Presented at: The 91st Annual Meeting of the Endocrine Society. Washington, USA, 10–13 June 2009.
   Google Scholar
• Hartwig W, Kasperlik-Zaluska A, Wilczynska J, Migdalska B. Cyproheptadine in pituitary disorders. N. Engl. J. Med.295, 394 (1976).
   PubMedGoogle Scholar
• Dornhorst A, Jenkins JS, Lamberts SWJ et al. The evaluation of sodium valproate in the treatment of Nelson’s syndrome. J. Clin. Endcrinol. Metab.65, 985–991 (1983).
   Google Scholar
• Casurali LA, Naves LA, Mello PA, Pereira Neto A, Papadia C. Nelson’s syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm. Res.62(6), 300–305 (2004).
   PubMedGoogle Scholar
• Shraga-Slutzky I, Shimoni, Weinhstein R. Clinical and biochemical stabilization of Nelson’s syndrome with long-term low-dose cabergoline treatment. Pituitary9(2), 151–154 (2006).
   PubMedGoogle Scholar
• Kasperlik-Zaluska AA, Zgliczynski W, Jeske W, Zdunowski P. ACTH responses to somatostatin, valproic acid and dexamethasone in Nelson’s syndrome. Neuroendocrinol. Letters26(6), 709–712 (2005).
   PubMedGoogle Scholar
• Hofland FJ, van der Hoek J, Feelders R et al. The multiligand somatostatin analogue SOM 230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur. J. Endocrinol.152, 645–654 (2005).
   PubMed Web of Science ®Google Scholar
• Andreassen M, Kristensen LO. Rosiglitazone for prevention or adjuvant treatment of Nelson’s syndrome after bilateral adrenalectomy. Eur. J. Endocrinol.153, 503–505 (2005).
   PubMedGoogle Scholar
• Mullan KR, Leslie H, McCance DR, Sheridan B, Atkinson B. The PPAR-γ activator rosiglitasone fails to lower plasma ACTH levels in patients with Nelson’s syndrome. Clin. Endocrinol.64, 519–522 (2006).
   PubMed Web of Science ®Google Scholar
• Munir A, Song F, Ince P, Walters SJ, Ross R, Newell-Price J. Ineffectiveness of rosiglitazone therapy in Nelson’s syndrome. J. Clin. Endcrinol. Metab.92, 1758–1763 (2007).
   PubMed Web of Science ®Google Scholar
• Moyes VJ, Alusi G, Sabin HI et al. Treatment of Nelson’s syndrome with temozolomide. Eur. J. Endocrinol.160(1), 115–119 (2009).
   PubMed Web of Science ®Google Scholar
• Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD. Use of temozolomide in aggressive pituitary tumors. Neurosurgery64(4), 773–774 (2009).
   PubMed Web of Science ®Google Scholar
• Fadul C, Kominsky AL, Meyer LP et al. Pituitary carcinomas respond to temozolomide. Neuro. Oncol.6, 374 (2004).
   Google Scholar
• Kovacs K, Scheithauer BW, Lombardero M et al. MGMT immunosupression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol.115, 261–262 (2008).
   PubMedGoogle Scholar